Interestingly, the PARP inhibitor niraparib attenuated tumour growth in a mouse xenograft model with ovarian cancer cells expressing FOXQ1 [112], suggesting that PARP inhibition may have the additional benefit of counteracting FOXQ1 in cancer. This evidence concerns the gene FOXQ1 and cancer.